Stock AB AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

AB Science Stock

Equities

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:35:19 2024-06-07 am EDT 		5-day change 1st Jan Change
1.236 EUR -0.48% Intraday chart for AB Science -36.62% -65.23%
Jun. 03 AB Science: share price falls on resumption of trading CF
May. 30 Transcript : AB Science S.A. - Special Call

Financials

Sales 2023 970K 1.05M Sales 2024 * 990K 1.07M Capitalization 64.37M 69.51M
Net income 2023 -10M -10.8M Net income 2024 * -18M -19.44M EV / Sales 2023 187 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 65 x
P/E ratio 2023
-17.8 x
P/E ratio 2024 *
-3.43 x
Employees 89
Yield 2023 *
-
Yield 2024 *
-
Free-Float 64.06%
More Fundamentals * Assessed data

Chart AB Science

Dynamic Chart

Latest news about AB Science

AB Science: share price falls on resumption of trading CF
Transcript : AB Science S.A. - Special Call
AB Science: towards a negative opinion from the CHMP, listing suspended CF
AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AB Science: European patent granted for masitinib CF
AB Science: upbeat after legal success CF
French Appeals Court Acquits AB Science CEO of Insider Trading Charges MT
AB Science S.A. Announces Slight Delay in Publication of Annual Financial Report 2023 CI
AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
AB Science: reconsideration possible for masitinib in ALS CF
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS CI
AB Science: encouraging results for masitinib CF
Transcript : AB Science S.A. - Special Call
AB Science: share price falls, negative opinion in Canada CF
AB Science: share price falls, CHMP verdict postponed CF
More news

Latest transcript on AB Science

Logo AB Science
AB Science S.A. - Special Call
More transcripts

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30 GL
More recommendations

Press releases AB Science

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS GL
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS GL
AB Science reports its revenues for the year 2023 and provides an update on its activities GL
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036 GL
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient GL
More press releases

News in other languages on AB Science

AB Science : plus forte baisse du marché SRD à la clôture du jeudi 6 juin 2024 -
AB Science : Ordre du jour et texte des résolutions
AB Science : Bulletin de vote
AB Science : Rapport du Conseil d’Administration à l’Assemblée Générale mixte des Actionnaires du 26 juin 2024
AB Science : Rapport des commissaires aux comptes sur les comptes consolidés
More news

Quotes and Performance

1 day-0.48%
1 week-36.62%
Current month-36.62%
1 month-38.20%
3 months-44.07%
6 months-58.31%
Current year-65.23%
More quotes

Highs and lows

1 week
1.09
Extreme 1.09
1.70
1 month
1.09
Extreme 1.09
2.30
Current year
1.09
Extreme 1.09
4.47
1 year
1.09
Extreme 1.09
4.97
3 years
1.09
Extreme 1.09
16.68
5 years
1.09
Extreme 1.09
21.75
10 years
1.09
Extreme 1.09
21.75
More quotes

Managers and Directors - AB Science

Managers TitleAgeSince
Alain Moussy CEO
 Chief Executive Officer - 01-07-10
Laurent Guy DFI
 Director of Finance/CFO - 01-12-31
Christian Fassotte CTO
 Chief Tech/Sci/R&D Officer - 18-03-31
Members of the board TitleAgeSince
Alain Moussy CEO
 Chief Executive Officer - 01-07-10
Patrick Moussy BRD
 Director/Board Member - 01-07-10
Cécile de Guillebon BRD
 Director/Board Member 62 21-06-26
More insiders

ETFs positioned on AB Science

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.00% 10 M€ -3.35% -
More ETFs positioned on AB Science

Quotes

Date Price Change Volume
24-06-07 1.236 -0.48% 442,507
24-06-06 1.242 -11.03% 354,157
24-06-05 1.396 -5.16% 262,965
24-06-04 1.472 -7.42% 188,920
24-06-03 1.59 -18.46% 893,478

Real-time Euronext Paris, June 07, 2024 at 11:35 am EDT

More quotes

Company Profile

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.236 EUR
Average target price
6.895 EUR
Spread / Average Target
+457.85%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
AB SCIENCE Stock AB Science
-65.23% 69.57M
MERCK KGAA Stock Merck KGaA
+18.88% 80.5B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+14.11% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-14.14% 4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.39% 4.49B
YUHAN CORPORATION Stock Yuhan Corporation
+18.90% 4.44B
INDIVIOR PLC Stock Indivior PLC
+7.93% 2.19B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-28.40% 2.13B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+15.93% 2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-43.17% 1.78B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AB Stock